Esther Nonaishi Githui’s Post

News Update: SFDA CEO H.E. Prof. Dr. Hisham S. Aljadhey visited BGI main site in China. Founded in 1999, BGI is one of the world's leading life science and genomics organizations. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life. BGI Genomics #SFDA #BGI #MedicalDevices #RegulatoryAffairs #MedicalDevicesRegistration #Healthcare #Innovation #Genomics #SaudiArabia #China #PublicHealth #GlobalPartnerships #HealthTech #LifeSciences #Biomedicine #UniFusionBSC

Few researchers and organisations have the expertise, skills, and infrastructure to tackle #AMR and discover new #antibiotics. Long-term funding for #antibiotic development partnerships will help attract young scientists to the field and keep companies in anti-infective drug development. To secure a sustainable future for efforts of this scale, we call on government leaders, the private sector and other stakeholders to invest in the development of antibiotics and AMR research.   The AMR Accelerator is an Innovative Health Initiative (IHI) programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building #antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of our assets, infrastructures and expertise. Read more in our article: https://lnkd.in/eqGbRqmg Explore our results: https://lnkd.in/ebSUbVhB

According to a statement released by Kenya Medical Research Institute (KEMRI), the new laboratory will serve as a hub for training scientists in biotechnology research and development. It aims to expedite the creation of biotechnology products that can swiftly respond to biothreats or emerging pandemics. The facility will feature high biocontainment laboratories equipped with cutting-edge technology for disease surveillance, pathogen identification, and the design, discovery, and development of drugs, vaccines, and diagnostic kits. Prof. Elijah Songok, KEMRI's Acting Director General and Chief Executive Officer, expressed gratitude to President Ruto and the Japanese government for their support. He highlighted the significance of the investment in solidifying KEMRI's leadership role in research and development, ultimately contributing to improved health and wellbeing. Prof. Songok emphasized that the new facility will enable KEMRI to train a new generation of scientists, fostering expertise in medical research and local product development. #KEMRI #MedicalResearch #Biotechnology #Healthcare #Laboratory #ResearchAndDevelopment #KenyaJapanRelations #ScienceAndInnovation #Biosecurity #GlobalHealth #Grants #KenyaDevelopment #PublicHealth #PandemicResponse Please find the Media Release Here: https://lnkd.in/dPAs4arF

📣Highly-Cited Papers #Review The Role of Surface Enhanced Raman Scattering for Therapeutic Drug Monitoring of Antimicrobial Agents by Stefano Fornasaro, Dana Cialla-May, Valter Sergo and Alois Bonifacio   👉https://lnkd.in/emJxicB5 MDPI Università degli Studi di Trieste Friedrich Schiller University Jena University of Macau #antibiotics #SERS #biofluids #Ramanspectroscopy #TDM This article belongs to the Special Issue SERS: Analytical and Biological Challenges https://lnkd.in/gbHChRm

The thrill of scientific discovery and its potential to impact lives drives Han Ping Loh, PhD to push the boundaries of his research in bispecific antibody (bsAb) discovery. Han Ping’s curiosity in the field of science started from a young age which eventually led to him pursuing a PhD in Biological Sciences. Through this academic pursuit, he was introduced to the intricacies of cellular processes and the production of valuable biologics. The potential for real-world impact in this field ultimately guided his decision to join the Cell Line Development (CLD) group in #BTI. bsAb has proven to be a powerful immunotherapy tool, and Han Ping has made it his goal to overcome the many challenges that hamper bsAb's journey from bench to bedside. Presently, Han Ping coordinates a multidisciplinary team working towards advancing bsAb capabilities in the institute. The team’s work focuses on developing pioneer platform technologies that streamline bsAb discovery and screening. This will ultimately lead to lower production costs, making bsAb treatments more affordable and accessible to patients. When he’s not cultivating cells in the lab, he’s cultivating his >30 succulents in his indoor garden, propagating them from leaves or stem cuttings. Horticulture serves as a therapeutic escape, allowing him to unwind and recharge after work. Like his plants, he also enjoys exposure to daylight and fresh air – embarking on overseas hiking adventures with his wife whenever he can to refresh and enrich his mind. His personal mantra reflects his positive attitude: “Never try, never know.” Connect with us here: https://lnkd.in/gRU66bP #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #bsAb #antibodydiscovery #antibodies

“Dr 𝐀𝐦𝐚𝐝𝐨𝐮 𝐀𝐥𝐩𝐡𝐚 𝐒𝐚𝐥𝐥, CEO of Institut Pasteur de Dakar (IPD), and Cheikh Tidiane Diagne, Chief of #Diatropix, were deep in conversation about the future product and business model strategy of the #Dakar-based rapid diagnostics manufacturing platform set up by IPD. Against all odds, the start-up had built a manufacturing facility for #RapidDiagnosticTests (RDTs) and was producing #COVID19 and other self-tests in #Africa at affordable prices – over a million COVID-19 lateral flow tests in just a year. Having ridden the wave of need across Africa when governments needed a supply of COVID tests, now the Senegalese start-up had to refocus on its original mission of manufacturing a portfolio of RDTs for diseases found mainly in Africa that were neglected by large diagnostic companies. For Sall and Diagne, ensuring the business model was #sustainable was a top priority." "This was challenging in a market dominated by large test manufacturers and lowest cost pricing. Purchasers – both global (such as the Global Fund and USAID) and national – preferred the lowest cost supplier and large-scale competitors in India, China and South Korea enjoyed low costs of production. Competing on price would not make Diatropix sustainable. To secure its future, they had to answer two questions: Which products should they make? And what pricing strategy and monetising/business model to implement? “ 📗 In our new case “𝑫𝒊𝒂𝒕𝒓𝒐𝒑𝒊𝒙: 𝑪𝒓𝒆𝒂𝒕𝒊𝒏𝒈 𝒂 𝑺𝒖𝒔𝒕𝒂𝒊𝒏𝒂𝒃𝒍𝒆 𝑹𝒂𝒑𝒊𝒅 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒕𝒊𝒄 𝑻𝒆𝒔𝒕 𝑴𝒂𝒏𝒖𝒇𝒂𝒄𝒕𝒖𝒓𝒊𝒏𝒈 𝑷𝒍𝒂𝒕𝒇𝒐𝒓𝒎 𝒊𝒏 𝑨𝒇𝒓𝒊𝒄𝒂”, INSEAD Professors Prashant Yadav and 𝐋𝐮𝐤 𝐕𝐚𝐧 𝐖𝐚𝐬𝐬𝐞𝐧𝐡𝐨𝐯𝐞, alongside Dr Lisa Simone Duke, explore #Diatropix ’s journey as the company grapples with the challenges of a hyper-competitive #globalmarket and explores a new #businessmodel to compete. To learn more about the #operationsstrategy and potential of a subscription-based model in the #medicaldevices industry, check out the case on our website https://lnkd.in/gwdWz8Ti   INSEAD Business Sustainability Program INSEAD Sustainable Business Initiative INSEAD Humanitarian Research Group #INSEADcases #casestudies #newcases #marketentry #SubscriptionBusinessModel #diagnostics #sdg3 #goodhealthandwellbeing

Save the dates

***EUbOPEN opens its gates to a library of chemical compounds*** Enabling and unlocking biology in the OPEN (#EUbOPEN), a project of the Innovative Medicines Initiative (IMI), is an international consortium which is lead by Prof. Dr. Stefan Knapp from the Goethe-Universität Frankfurt. The Innovative Health Initiative (IHI) recognized EUbOPEN as a research highlight in its new brochure “IHI 2023 In Focus“. When developing new medicines, scientists aim to understand the underlying causes of #diseases. To achieve this, they study the role of different #proteins involved in the disease process. This requires chemical compounds that can alter or block the action of individual proteins. By the end of 2023, the EUbOPEN Gateway provided scientists with access to a library of 2300 precisely annotated chemical compounds covering approximately 850 different proteins. The EUbOPEN team’s goal is to create the largest and most deeply characterized open collection of #chemical modulators for protein function. Additionally, 88 high-quality probe compounds, co-developed by academics and #pharmaceutical industries, are now available to the global scientific community. These initiatives empower researchers in academia and industry to design #drugs that target specific disease-related proteins and enhance our understanding of disease mechanisms. You will find further information here: https://lnkd.in/dhu5YA6y

⏳ The clock is running: less than ONE month to go for the next evaluation! ENABLE-2 INCUBATOR - HIT IDENTIFICATION AND VALIDATION Compound eligibility criteria: • Novel compounds with some documented whole cell antibacterial activity against any species or strain (including efflux-deficient or hyperpermeable strains), with a MIC of at least 32 µg/mL, or • Novel compounds with only documented bacterial target activity. • Potential for development as direct-acting antibiotics for systemic use. • Not previously reported to have antibacterial activity. • Antimicrobial peptides with only membrane perturbation activity are not eligible. • Novel natural products are eligible Who can apply? Researchers at publicly funded universities and research institutes in Europe (including non-EU countries such as UK, Norway, Switzerland etc.) are eligible. The call is open continuously. Expressions of Interest submitted by 30 August 2024 will be evaluated by end of September 2024. More info & Expression of Interest ➡ https://lnkd.in/d27wU4KZ #antimicrobialresistance #antibioticresistance #antibiotics #amr

🌟 Another Successful Webinar Completed! 🌟 Yesterday, Heredity Biosciences hosted an insightful webinar on "Nanotoxicity: A Challenge for Future Medicines." A huge thank you to Dr. Piyush Kumar Gupta 🇮🇳 for delivering an exceptional talk and sharing valuable insights. We're also grateful to all our active participants for their enthusiastic engagement and contributions to the discussion. 🎥 If you missed the live session, don't worry! You can now watch the recording at your convenience. Click the link below to access the webinar recording: [https://lnkd.in/gSXssW3r) Don't miss out on this opportunity to learn and stay informed about the latest developments in nanotoxicity research. Watch the recording today and enhance your knowledge in this important field. #Nanotoxicity #FutureMedicine #HeredityBiosciences #WebinarRecording #Science #Research #LearningOpportunity #hereditybio